I am a (postdoctral fellow) at (MGH) studying (neuroscience-sepcifically Alzheimer's formation).
I have a (strong molecular biology and cell biology) background. I have worked on (collaborative projects and enjoy team settings). I am looking for a (research role) in a (smaller biotech).
I am very interested in this opportunity since I will be able to apply (my skills to understand specific disease progeression) and (work in an entrepreneurial setting)".
Prior to Propel Careers, Lauren was a senior account manager for SNBL USA where she worked with emerging biotech companies in Europe, Asia, and the US to help characterize and advance their drug molecules. Prior to SNBL USA, she held business development positions with Aptuit and Quintiles, where she focused on IND enabling studies to advance therapeutics from discovery into the clinic. Earlier in her career, Lauren held positions as a marketing manager and account manager at Absorption Systems, where she was responsible for managing life sciences companies in the northeastern United States. She has a B.S. in Biochemistry and Molecular Biology from Gettysburg College and an MBA with a focus in the health sector and entrepreneurship from Boston University. Lauren is on the Board of MassBioEd, the Advisory Board of the Boston University School of Public Health Pharmaceuticals Program, and the Advisory board for Endicott College Boston. She also serves on the programming committee of the Capital Network.
ターゲットはSBIR(Small Business Innovation Research)というアメリカののトランスレーショナルリサーチ向けのグラントの書き方のレクチャーであったが、基本のグラントとなっている、NIHのグラントに準じているため、いろいろな情報は別のグラントを書くのにも使えそうで大変参考になった(*)。
ある調査で各構成要素の点数のうちどれと一番相関があるかを計算したところ、0.74 for approach, 0.54 for innovation, 0.49 for investigator and 0.37 for environmentとなるらしく、preliminary dataを含めた計画の部分がものをいうということであった。
1)Abstract (Publically available)
The significance
The problems
The solution
The plans
の4つのポイントを上記の構成で、簡潔に書く。
2)Specific aim
1) Significance(重要性)
(例)シャーガス病は、アメリカの輸血での感染症の新しい脅威となっている
2) Problem and solution(問題の定義)
(例)シャーガス病の迅速検査キットを作ることで、輸血による感染を防ぐごとができる
3) Aim (多すぎてはいけない)
(例)
1) Development of a prototype
2) Preliminary Characterization
2)Innovation
(1)Impact & cost efficiency
(2)Etiology & unmet need
★Be clear what is innovative in your proposal?
そのためには申請中のものも含め特許があるとよい
またConfidentialな情報も、confidentialであると脚注をつけて、具体的に記述した方がよい。
★用語の使い方も注意。単にImmunoassayといってどこが新たしいのと思われるよりより、a novel reporter chemistryといった方がよいこともある。
3)Approach
研究計画のセクション、一番グラントが取れるかどうかを決めるのに重要なセクションである
(1)Preliminary data
Not too much and not too little:多すぎると、この計画をやるのは意味がないと思われる。少なすぎると、プロポーザルの信憑性を上げるのには足らない
Model experiments (シュミレーション?) VS Actual dataは実際のデーターがよいのはもちろんのこと。
Collaborators: Expertise in the field, complimentary expertise, access to the resources, letter of support (write it by yourself, and make it say what you expect)
さらにこのチームの信憑性を増すような言葉をいれるべし。自分で言った言葉とともに他人の言葉として、それが入っていることは大きい。
4)Biosketch
Personal statement の部分で、supportiveな情報を入れこめ
5)letters of support from Collaborators
★write it by yourself, and make it say what you expect さらにこのチームの信憑性を増すような言葉をいれるべし。自分で言った言葉とともに他人の言葉として、それが入っていることは大きい。
This workshop led by Dr. Andrew Levin (CEO of Immunetics) will focus on the tactics and practical elements that give you the best shot at a successful SBIR grant application, in particular to the National Institutes of Health. Topics will include how to prepare for a new application, how to write for maximal impact, how to take advantage of collaborations, how to see the application from the reviewer’s point of view, how to avoid simple mistakes that lead to rejection, how the non-scientific components of an application need to support the science, how applications are scored during the review, what to do if your application doesn’t succeed on the first try, and more. Practical examples drawn from actual grant applications - both funded and not funded - and the associated reviews will be presented. The workshop is aimed both at first time grant writers and those with prior experience.
Dr. Levin is President, Founder and Scientific Director of Immunetics, Inc., a leading innovator of assay technology for infectious disease research and diagnosis. He has been awarded over 25 grants and contracts totaling over $40 million by NIH and CDC, making Immunetics one of the top small business recipients of federal funding in Boston. He is currently focused on launching new tests for bacterial and parasitic agents to address infectious threats to blood transfusion safety. Dr. Levin received his A.B. in Biochemistry from Princeton University and his Ph.D in Molecular Biology from the University of Wisconsin, after which accepted an NIH Postdoctoral Fellowship at Harvard University.
•Specific aims
•Background and significance
•Preliminary data
•Experimental design and methods
•Potential scientific and medical impact
•References
であることが多い。
ボスから言われた注意点としては
•一年のグラントであればAimは1-2ぐらいが限度。三年くらいだと3個くらいらしい。
•summary or abstructの字数に余裕があれば、そこにもAimを入れておいた方がよい。
•Preliminary dataは、あるデータ全部でなくショッキングなものを、ちら見させる感じで。。
(Marketing Scientistsという本でも同じようなコメントがある)
•Potential scientific and medical impactには、予想される結果とその意義、future plan, また予想通りの結果が出なかったときの対処法や意味ある結果の出し方などを盛り込むとよい。